CDK
Os inibidores das quinases dependentes de ciclinas (CDK) são compostos que bloqueiam a atividade das CDKs, um grupo de quinases de proteínas que regulam o ciclo celular, a transcrição e outros processos celulares. As CDKs são ativadas pela ligação às ciclinas, e sua atividade é crucial para a progressão das células através das diferentes fases do ciclo celular. Inibir as CDKs pode interromper a divisão celular, levando à parada do ciclo celular e à apoptose, especialmente em células cancerígenas onde as CDKs frequentemente estão desreguladas. Os inibidores de CDK são amplamente utilizados na pesquisa do câncer e têm potencial terapêutico no tratamento de vários tipos de câncer. Na CymitQuimica, oferecemos uma seleção abrangente de inibidores de CDK de alta qualidade para apoiar sua pesquisa em controle do ciclo celular, câncer e desenvolvimento terapêutico.
Foram encontrados 500 produtos de "CDK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
AMG 925
CAS:<p>AMG 925 is a potent and orally bioavailable dual FLT3/CDK4 inhibitor with IC50 of 1 nM and 3 nM, respectively.</p>Fórmula:C26H29N7O2Pureza:99.75%Cor e Forma:SolidPeso molecular:471.55CID44216842
CAS:<p>CID44216842 is a potent Cdc42-selective inhibitor with EC50: 1.0μM (WT), 1.2μM (Q61L) in GTP assay; 0.3μM (WT), 0.5μM (Q61L) in GDP assay. Use as a probe.</p>Fórmula:C22H20BrN3O3SPureza:99.66%Cor e Forma:SolidPeso molecular:486.38CVT-313
CAS:<p>CVT-313 (NG-26) is a potent, selective, reversible, and ATP-competitive inhibitor.</p>Fórmula:C20H28N6O3Pureza:97.46% - 97.97%Cor e Forma:SolidPeso molecular:400.47GSK 3 Inhibitor IX
CAS:<p>GSK 3 Inhibitor IX (6-BIO) is a selective reversible, ATP-competitive inhibitor of GSK-3α/β and CDK1-cyclinB complex.</p>Fórmula:C16H10BrN3O2Pureza:98% - 99.72%Cor e Forma:SolidPeso molecular:356.17Purvalanol B
CAS:<p>Purvalanol B (NG 95) is a CDK inhibitor that inhibits Cdk2/cyclin A, Cdk2/cyclin E, Cdk5/p35, and Cdk2/cyclin B (IC50s = 6, 9, 6, and 6 nM, respectively)</p>Fórmula:C20H25ClN6O3Pureza:98.95%Cor e Forma:SolidPeso molecular:432.9Palbociclib monohydrochloride
CAS:<p>Palbociclib monohydrochloride (PD 0332991 hydrochloride) is a selective inhibitor of CDK4/6, with no inhibition against a panel of 36 additional protein kinases</p>Fórmula:C24H29N7O2·HClPureza:99.73% - >99.99%Cor e Forma:SolidPeso molecular:483.99Toyocamycin
CAS:<p>Toyocamycin (Vengicide) is an adenosine analog produced by Actinomycete, acts as an XBP1 inhibitor, inhibits IRE1α-induced ATP-dependent XBP1 mRNA cleavage (</p>Fórmula:C12H13N5O4Pureza:98.1% - 98.17%Cor e Forma:SolidPeso molecular:291.26Wogonin
CAS:<p>Wogonin (Vogonin) is a cell-permeable and orally available flavonoid that displays anti-inflammatory and anticancer properties.</p>Fórmula:C16H12O5Pureza:98% - 99.8%Cor e Forma:Yellow CrystalPeso molecular:284.26Palbociclib Isethionate
CAS:<p>Palbociclib Isethionate (PD 0332991 isethionate) 是一种高选择性的CDK4/6抑制剂，IC50为11 nM 和16 nM。它对一组 36 种额外的蛋白激酶没有抑制作用。</p>Fórmula:C24H29N7O2·C2H6O4SPureza:99.01% - 99.27%Cor e Forma:SolidPeso molecular:573.66SU9516
CAS:<p>SU9516 is a potent CDK2 inhibitor, with an IC50 of 22 nM, and also has inhibitory effects on CDK1 and CDK4, with IC50s of 40 nM and 200 nM, respectively.</p>Fórmula:C13H11N3O2Pureza:99.34% - 99.87%Cor e Forma:SolidPeso molecular:241.25BI-1347
CAS:<p>BI-1347 is a potent, selective inhibitor of CDK8/cyclinC (IC50: 1 nM). It shows tumor growth inhibition in an in vivo xenograft model.</p>Fórmula:C22H20N4OPureza:96.7% - 99.63%Cor e Forma:SolidPeso molecular:356.42SRI-29329
CAS:<p>SRI-29329 is a potent, specific inhibitor of CDC-like kinase (with IC50 of 78 nM, 16 nM and 86 nM for CLK1, CLK2 and CLK4, respectively).</p>Fórmula:C20H26ClN7Pureza:99.18%Cor e Forma:SolidPeso molecular:399.92NSC23005
CAS:<p>NSC23005 sodium is a p18INK inhibitor with potently promoted hematopoietic stem cell (HSC) expansion (ED50: 5.21 nM).</p>Fórmula:C13H17NO4SPureza:>99.99%Cor e Forma:SolidPeso molecular:283.34AT7519
CAS:<p>AT7519 is a CDK1/2/4/6/9 inhibitor (IC50: 10-210 nM). It is less effective to CDK3 and little active to CDK7.</p>Fórmula:C16H17Cl2N5O2Pureza:98.88% - 99.65%Cor e Forma:SolidPeso molecular:382.24(E/Z)-TG003
CAS:<p>(E/Z)-TG003 is a potent and ATP-competitive Cdc2-like kinase (Clk) inhibitor.</p>Fórmula:C13H15NO2SPureza:98% - 99.04%Cor e Forma:SolidPeso molecular:249.33TP-353
CAS:<p>TP-353 (EOS-61973) is a CDK7 inhibitor.</p>Fórmula:C35H30FNO3Pureza:99.12%Cor e Forma:SolidPeso molecular:531.62Trilaciclib
CAS:<p>Trilaciclib is a short-acting, orally effective CDK4/6 inhibitor with IC₅₀ values of 1 nM and 4 nM respectively. enhances antitumour immunity.</p>Fórmula:C24H30N8OPureza:99.624%Cor e Forma:SolidPeso molecular:446.55AZ5576
CAS:<p>AZ5576 is a potent and highly selective CDK9 inhibitor. AZ5576 can be used for the research of Hematological Malignancy [1].</p>Fórmula:C21H24FN3O3Pureza:99.88%Cor e Forma:SoildPeso molecular:385.43CDK12-IN-5
CAS:<p>CDK12-IN-5 is a potent CDK12 inhibitor with potential anticancer and antitumor activity, and can be used orally in the study of breast and ovarian cancer.</p>Fórmula:C18H15F5N8OPureza:99.37%Cor e Forma:SolidPeso molecular:454.36LSN2839567
CAS:<p>LSN2839567 (Abemaciclib metabolite M2) is a CDK4 and CDK6 inhibitor with anticancer activity, inhibits CDK9, and can be used in breast cancer research.</p>Fórmula:C25H28F2N8Pureza:99.14%Cor e Forma:SolidPeso molecular:478.54(R)-(+)-O-Demethylbuchenavianine
CAS:<p>(R)-(+)-O-Demethylbuchenavianine is a cyclin-dependent kinase (CDK) inhibitor. It inhibits CDK1, CDK5, glycogen synthase kinase 3 (GSK3), cdc2-like kinase (CLK1), and dual-specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) with IC50 values of 1.1 μM, 0.95 μM, >10 μM, >10 μM, and >10 μM, respectively.</p>Fórmula:C21H21NO4Cor e Forma:SolidPeso molecular:351.40Riviciclib hydrochloride
CAS:<p>Riviciclib hydrochloride (P276-00) is a novel CDK1, CDK4 and CDK9 inhibitor with IC50 of 79 nM, 63 nM and 20 nM, respectively. Phase 2/3.</p>Fórmula:C21H20ClNO5·HClPureza:99.51%Cor e Forma:SolidPeso molecular:438.3XL413
CAS:<p>XL-413 is an oral CDC7 kinase inhibitor, potentially blocking DNA replication, mitosis, and cancer cell growth.</p>Fórmula:C14H12ClN3O2Pureza:98.40% - >99.99%Cor e Forma:SolidPeso molecular:289.72MFH290
CAS:<p>MFH290 is a selective CDK12/13 inhibitor, covalently bonding with CDK12 Cys-1039, blocks Pol II CTD phosphorylation, and enhances olaparib's efficacy.</p>Fórmula:C26H31N5O3S2Cor e Forma:SolidPeso molecular:525.69CDK2-IN-13
CAS:<p>CDK2-IN-13: Potent CDK2 inhibitor, arrests cell cycle, induces apoptosis, IC50=12 µM, used in cancer research.</p>Fórmula:C13H12ClN5Cor e Forma:SoildPeso molecular:273.72CDK8-IN-4
CAS:<p>CDK8-IN-4 is an inhibitor of CDK8 (IC50: 0.2 nM).</p>Fórmula:C20H18N4OCor e Forma:SolidPeso molecular:330.38CDK12-IN-3
CAS:<p>CDK12-IN-3 is a CDK12 inhibitor with anti-tumor activity and can be used for the study of malignant tumors.</p>Fórmula:C23H28F2N8OPureza:99.85%Cor e Forma:SolidPeso molecular:470.52Cdc7-IN-5
CAS:<p>Cdc7-IN-5: potent Cdc7 serine-threonine kinase inhibitor, critical for starting DNA replication.</p>Fórmula:C25H23N3O5Pureza:97.15%Cor e Forma:SolidPeso molecular:445.47Cdc7-IN-9
CAS:<p>Cdc7-IN-9 can be used for the research of cancer which is a potent inhibitor of Cdc7 [1].</p>Fórmula:C15H17N5OSCor e Forma:SolidPeso molecular:315.39SNX2-1-108
CAS:<p>SNX2-1-108 is a selective CDK8 and CDK19 inhibitor.</p>Fórmula:C21H16N4Pureza:98%Cor e Forma:SolidPeso molecular:324.38Metralindole HCl
CAS:<p>Metralindole is a reversible monoamine oxidase A (RIMA) inhibitor, it was investigated as a potential antidepressant.</p>Fórmula:C15H18ClN3OPureza:98%Cor e Forma:SolidPeso molecular:291.78CDK7-IN-15
CAS:<p>CDK7-IN-15, a pyrimidine-based potent CDK7 inhibitor, shows promise for various cancers with defective transcription.</p>Fórmula:C21H24F4N6OSCor e Forma:SolidPeso molecular:484.51BAY-958
CAS:<p>BAY-958 is a potent and selective inhibitor of PTEFb/CDK9.</p>Fórmula:C17H16FN5O3SPureza:98%Cor e Forma:SolidPeso molecular:389.4EGFR/CDK2-IN-1
CAS:<p>EGFR/CDK2-IN-1, an inhibitor of both EGFR and CDK2, demonstrates effective cytotoxicity towards MCF7 and HepG2 cells, suggesting its potential application in</p>Fórmula:C19H12BrClO2Cor e Forma:SolidPeso molecular:387.65CDK7-IN-10
CAS:<p>CDK7-IN-10: CDK7 inhibitor, IC50<100 nM, may hinder cell growth, induce apoptosis. (Patent WO2021016388A1, I-1)</p>Fórmula:C29H35N7O3Cor e Forma:SolidPeso molecular:529.63CDK7-IN-16
CAS:<p>CDK7-IN-16, a potent CDK7 inhibitor (IC50: 1-10 nM), is used in cancer research with transcription defects.</p>Fórmula:C19H21F3N6O2SCor e Forma:SolidPeso molecular:454.47Ipivivint
CAS:<p>Ipivivint: orally active, potent CLK inhibitor; hinders CLK1, CLK2, & CLK3; curbs Wnt signaling & SRSF phosphorylation for cancer research.</p>Fórmula:C26H21FN8Cor e Forma:SolidPeso molecular:464.5NSC 693868
CAS:<p>CDKs and GSK-3 inhibitor</p>Fórmula:C9H7N5Pureza:98%Cor e Forma:SolidPeso molecular:185.19Atuveciclib S-Enantiomer
CAS:<p>Atuveciclib S-Enantiomer is a (S)-form of BAY-1143572; a potent, selective CDK9 inhibitor with an IC50 of 16 nM.</p>Fórmula:C18H18FN5O2SPureza:98%Cor e Forma:SolidPeso molecular:387.43CDK8-IN-6
CAS:<p>CDK8-IN-6 (compound 9) is a potent inhibitor of cyclin-dependent kinase 8 (CDK8) (Kd: 13 nM), CDK8-IN-6 showed potential research value in AML cancers.</p>Fórmula:C26H37ClN2Cor e Forma:SolidPeso molecular:413.04CDK4/6-IN-14
CAS:<p>CDK4/6-IN-14: potent CDK4/6 inhibitor, IC50s 10/16 nM, >60-fold selectivity over CDKs 1/2/7/9, selective across 205 kinases.</p>Fórmula:C24H27ClFN7OCor e Forma:SolidPeso molecular:483.97KH-CB19
CAS:<p>KH-CB19 is an effective and highly specific inhibitor of the CDC2-like kinase isoforms 1 and 4 (CLK1/CLK4).</p>Fórmula:C15H13Cl2N3O2Cor e Forma:SolidPeso molecular:338.19Cdc7-IN-14
CAS:<p>Cdc7-IN-14 (compound 82) is a potent CDC7 inhibitor with an IC50 < 1 nM, promising for cancer research.</p>Fórmula:C18H20N4O2SCor e Forma:SolidPeso molecular:356.44CDK9-IN-15
CAS:<p>CDK9-IN-15: potent CDK9 inhibitor, blocks P-TEFb phosphorylation, inhibits transcription, reduces mRNA, induces tumor cell apoptosis.</p>Fórmula:C16H11N3OSPureza:97.24%Cor e Forma:SolidPeso molecular:293.34CDK-IN-10
CAS:<p>CDK-IN-10 is a cell cycle protein-dependent kinase (CDK) inhibitor with potential anticancer activity for cancer research.</p>Fórmula:C18H18N4O2Pureza:97.07%Cor e Forma:SolidPeso molecular:322.36CLK1-IN-2
<p>CLK1-IN-2: Metabolically stable, Clk1-selective inhibitor; IC50=1.7nM; useful in tumor, Duchenne MD, HIV-1, influenza research.</p>Fórmula:C16H12Cl2N2O2SCor e Forma:SolidPeso molecular:367.25XIE18-6
CAS:<p>XIE18-6 is a novel INK4C inhibitor that blocks p18 activity and promotes ex vivo expansion of human and murine hematopoietic stem cells.</p>Fórmula:C18H15NO6SPureza:99.712%Cor e Forma:SolidPeso molecular:373.38NSC 625987
CAS:<p>Cyclin-dependent kinase (cdk) 4 inhibitor</p>Fórmula:C15H13NO2SPureza:98%Cor e Forma:SolidPeso molecular:271.33ARN22089
CAS:<p>ARN22089 is an oral active CDC42 GTPase interaction inhibitor that blocks tumour growth in BRAF mutant mouse melanoma models and PDXs in vivo.</p>Fórmula:C23H27N5Pureza:98.37%Cor e Forma:SolidPeso molecular:373.49CDK8/19-IN-51
CAS:<p>CDK8/19-IN-51 is a CDK8 and CDK19 inhibitor with anticancer activity, used in research on colorectal and gastric cancers.</p>Fórmula:C23H22N6O2Pureza:98.65% - 99.62%Cor e Forma:SoildPeso molecular:414.46
